The global lymphoma treatment market
size is expected to reach USD 26.4 billion by 2026, exhibiting a CAGR of 9.5%.
Rising research activities for development of new treatments and increasing
product line extension are likely to expedite growth. Increasing
commercialization of novel drugs are further expected to drive the growth.
Access
Sample Report of this report @ https://www.radiantinsights.com/research/lymphoma-market/request-sample
Availability of wide variety of products
is further expected to aid growth. For instance, in January 2019, BeiGene
received a breakthrough therapy designation by the U.S. FDA for its product
Zanubrutinib for treating mantle cell lymphoma in adults. This drug is
currently in late-stage clinical trial and is expected to be launched during
the forecast period.
Growing awareness about early diagnosis
of lymphoma among healthcare professionals & patients and rising government
funding for R&D are some factors expected to propel market growth. For
instance, institutes such as National Cancer Institute receives funding from the
U.S. Congress to support cancer-related research and associated activities.
Further
key findings from the report suggest:
• Non-Hodgkin lymphoma held the largest
share in 2018 owing to prevalence of non-Hodgkin lymphoma and presence of
blockbuster drugs.
• Hodgkin lymphoma is expected to be the
fastest growing segment due to presence of strong product pipeline and increase
in the number of label extension for existing drugs.
• Based on drug, Revlimid held the
highest share in 2018 and is expected to grow at a significant rate during the
forecast period. This can be attributed to growing use of this product in
cancer treatment regimens.
• Rituxan/MabThera held the second
largest share in 2018 owing to increasing use of this product in multiple
indications and high prescription rate in major markets such as the U.S.,
Europe, and Japan.
• North America dominated in 2018,
followed by Europe. This can be attributed to well-established healthcare
infrastructure, high R&D expenditure, availability of novel drugs, and
presence of key players.
• Asia Pacific is expected to be the
fastest growing over the forecast period owing to increase in commercialization
of products, rise in awareness about diseases and high unmet clinical needs.
• Some of the major players are Celgene
Corporation; Bristol-Myers Squibb Company; F. Hoffmann-La Roche Ltd.; Seattle
Genetics, Inc.; Merck & Co., Inc.; Johnson & Johnson; Takeda
Pharmaceutical Company Ltd.; Abbott Laboratories; and Eli Lilly and Company.
• Key players for lymphoma treatment
market are adopting strategies such as collaborations, mergers &
acquisitions, product development, product line extension, and regional
expansion to increase their share. For instance, Seattle Genetics collaborated
with Takeda Pharmaceuticals for commercialization of Adcetris in different
regions other than North America.
Read
Complete Report with TOC @ https://www.radiantinsights.com/research/lymphoma-market
About
Radiant Insights
Radiant Insights is a platform for
companies looking to meet their market research and business intelligence
requirements. We assist and facilitate organizations and individuals procure
market research reports, helping them in the decision making process. We have a
comprehensive collection of reports, covering over 40 key industries and a host
of micro markets. In addition to over extensive database of reports, our experienced
research coordinators also offer a host of ancillary services such as, research
partnerships/ tie-ups and customized research solutions.
Media
Contact:
Michelle Thoras
201 Spear Street 1100,
Suite 3036, San Francisco,
CA 94105, United States
Tel: 1-415-349-0054
Toll Free: 1-888-928-9744
Mail: sales@radiantinsights.com
No comments:
Post a Comment